Table 1. Characteristics of NL cohort in 2016 and 2019 and comparison with CANOC.
| Characteristic | Category | Descriptive Statistics | |||||
|---|---|---|---|---|---|---|---|
| NL 2016 | NL 2019 | CANOC 2016 | |||||
| n = 177 | n = 188 | n = 11768 | |||||
| n | (%) | n | (%) | n | (%) | ||
| Age (years) | Median (IQR) | 50 (44–55) | 53 (46–57) | 47 (38–54)b | |||
| Gender | Male | 137 | (77) | 143 | (76) | 9744 | (83) |
| Female | 40 | (23) | 44 | (23) | 1963 | (17) | |
| Transgender | 0 | (0) | 1 | (1) | 55 | (0) | |
| Unknown | 0 | (0) | 0 | (0) | 6 | (0) | |
| Born In Canada | No | 12 | (7) | 17 | (9) | 1512 | (13) |
| Yes | 163 | (92) | 165 | (88) | 2513 | (21) | |
| Unknown | 2 | (1) | 6 | (3) | 7743 | (66) | |
| HIV Risk MSM | 91 | (51) | 100 | (53) | 5669 | (48) | |
| HIV Risk Heterosexual | 78 | (44) | 71 | (38) | 2538 | (22) | |
| HIV Risk IDU | 19 | (11) | 14 | (7) | 2478 | (21) | |
| HIV Risk Blood products | 4 | (2) | 5 | (3) | 177 | (2) | |
| HIV Risk Endemic country | 11 | (6) | 16 | (9) | 726 | (6) | |
| HIV Risk Perinatal transmission | 1 | (1) | 2 | (1) | 8 | (0) | |
| Age of Starting cART (years) | Median (IQR) | 37 (31–45) | 37 (31–46) | 39 (32–47)b | |||
| Baseline CD4+ T cell (cells/μL) | Median (IQR) | 384 (160–529) | 364 (164–558) | N/A | |||
| HIV Duration (years) | Median (IQR) | 13 (4–22) | 15 (6–25) | 8 (4–13)b | |||
| CD4+ T cell (cells/mL) | Median (IQR) | 621 (396–820) | 672 (422–920) | N/A | |||
| Time to cART Initiation | 0–12 months | 121 | (68) | 124 | (66) | 2682 | (23) |
| > 12 months | 48 | (27) | 48 | (26) | 4122 | (35)b | |
| Unknown | 8 | (5) | 16 | (9) | 4964 | (42) | |
| Duration on cART (years) | Median (IQR) | 11 (3–18)a | 11 (5–21) | 6 (3–10)b | |||
| Ever Diagnosed with AIDS-defining Illness | 41 | (23) | 46 | (24) | 2208 | (19) | |
| On cART | 175 | (99) | 184 | (98) | 10190 | (99) | |
| On cART and undetectable viremia | 162 | (93) | 176 | (96) | 8889 | (87) | |
| Hepatitis B (ever co-infected) | 17 | (10) | 18 | (10) | 1314 | (11) | |
| Hepatitis C (ever co-infected) | 20 | (11) | 19 | (10) | 2644 | (22)b | |
| Cytomegalovirus IgG | Never co-infected | 29 | (16) | 28 | (15) | N/A | N/A |
| Coinfected | 144 | (81) | 155 | (82) | N/A | N/A | |
| Unknown | 4 | (2) | 5 | (3) | N/A | N/A | |
| Ever Diagnosed with Cancer | 15 | (8) | 17 | (9) | 380 | (3)b | |
aDenotes p < 0.05 for significant difference in comparing NL (2016) vs NL (2019).
bDenotes p < 0.05 for significant difference in comparing NL (2016) vs. CANOC (2016) and associated with probability of indicated cohort more likely to have the higher value.